Details of the Drug
General Information of Drug (ID: DM9XV16)
Drug Name |
Sanguiin H-6
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Sanguiin H-6; CHEMBL508647; CHEMBL3734788; BDBM50250999; [[5-[dodecahydroxy(tetraoxo)[ ]yl]oxycarbonyl-2,3-dihydroxy-phenoxy]-dodecahydroxy-tetraoxo-[ ]yl] 3,4,5-trihydroxybenzoate; .alpha.-D-Glucopyranose, cyclic 4,6-[3-[5-[[[2,3:4,6-bis-O-[(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-diyl)dicarbonyl]-.beta.-D-glucopyranosyl]oxy]carbonyl]-2,3-dihydroxyphenoxy]-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] cyclic 2,3-(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate) 1-(3,4,5- trih
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 1871.3 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 4.2 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 29 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 52 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References